Loading...
Market
What will be the next major milestone for AI-based ROBO1 CAR T cell therapy for glioblastoma by end of 2024?
2
Resolution / Starting Odds
Successful Phase I trial • 25%
FDA Fast Track designation • 25%
Publication of promising preclinical results • 25%
No major milestone achieved • 25%
Official announcements from research institutions or publications in reputable medical journals
Story
Researchers Develop AI-Based Immunotherapy for Glioblastoma Using ROBO1 CAR T Cells
Aug 2, 2024, 09:09 AM
Researchers are pioneering a new immunotherapy approach using artificial intelligence (AI) to treat glioblastoma, a highly aggressive form of brain cancer. This innovative method, developed by scientists at institutions including Keck School of Medicine at USC and Cambridge University, aims to transform cancer treatment. The approach involves developing AI models to create new tools for combating cancer. A promising therapy treatment has been discovered that can kill glioblastoma cells by targeting a newly-discovered brain pathway, as reported in Nature Medicine. Additionally, the use of ROBO1 CAR T cells has shown potential as a potent immunotherapy for glioblastoma and other invasive brain cancers. This Canadian-developed treatment could significantly impact the fight against the most aggressive brain cancers.
View original story
Similar markets
Improved efficacy • 25%
Reduced side effects • 25%
Lower cost of treatment • 25%
Other • 25%
New drug approval • 25%
Major clinical trial success • 25%
New treatment guidelines • 25%
Other • 25%
Machine Learning • 25%
Deep Learning • 25%
Natural Language Processing • 25%
Other • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Other • 25%
Increased survival rate • 25%
Reduced secondary cancer rate • 25%
Improved quality of life • 25%
Other • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Yes • 50%
No • 50%
Successful with significant results • 25%
Moderate success with some positive results • 25%
No significant results • 25%
Trial halted or inconclusive • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial halted • 25%
Proof-of-concept data achieved • 25%
Partnership announcement • 25%
Regulatory approval submission • 25%
No major milestone achieved • 25%
